All Articles

Unlike side effects associated with common cancer treatments like chemotherapy and radiation, side effects from immunotherapy can arise months or even years after treatment is completed and can affect any organ system.

In the phase 3 CLL14 trial, fixed-duration therapy with the combination of venetoclax plus obinutuzumab was superior to the combination of chemotherapy with chlorambucil plus obinutuzumab as frontline therapy in older patients with chronic lymphocytic leukemia (CLL) and comorbidities.

Gilteritinib, a recently approved FLT3 inhibitor, prolonged survival in patients with relapsed or refractory acute myeloid leukemia (AML) and an FLT3 mutation in the phase 3 ADMIRAL clinical trial.

An Interview with Donna Moore Wilson, RN, MSN, CBCN, of the Virginia Cancer Patient Navigator Network

On September 26, 2019, the FDA approved daratumumab (Darzalex; Janssen) in combination with bortezomib, thalidomide, and dexamethasone for the treatment of newly diagnosed patients with multiple myeloma who are eligible for autologous stem-cell transplant (ASCT). The FDA granted this application priority review.

Oncology navigation encompasses countless topics in the world of oncology.

The authors evaluate the effects of yoga on physiological and psychosocial side effects of chemotherapy and biotherapy.

Ovarian cancers with BRCA mutations are less immunogenic than other DNA repair–deficient tumors.

Patients with ovarian cancer can respond to immunotherapy, but rationally designed synergistic combinations will be necessary to enhance upfront efficacy and to sustain durability, said Daniel J. Powell, Jr, PhD, Scientific Director of Immunotherapy, Division of Gynecologic Oncology, University of Pennsylvania, Philadelphia, at the 2019 ASCO-SITC Clinical Immuno-Oncology Symposium.